Literature DB >> 25135832

Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Qingsheng Li1, Ming Zeng1, Lijie Duan1, James E Voss2, Anthony J Smith1, Stefan Pambuccian3, Liang Shang1, Stephen Wietgrefe1, Peter J Southern1, Cavan S Reilly4, Pamela J Skinner5, Mary L Zupancic1, John V Carlis6, Michael Piatak7, Diane Waterman8, R Keith Reeves9, Katherine Masek-Hammerman9, Cynthia A Derdeyn10, Michael D Alpert11, David T Evans11, Heinz Kohler12, Sybille Müller13, James Robinson14, Jeffrey D Lifson7, Dennis R Burton2, R Paul Johnson15, Ashley T Haase16.   

Abstract

We sought design principles for a vaccine to prevent HIV transmission to women by identifying correlates of protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal model. We show that SIVmac239Δnef vaccination recruits plasma cells and induces ectopic lymphoid follicle formation beneath the mucosal epithelium in the rhesus macaque female reproductive tract. The plasma cells and ectopic follicles produce IgG Abs reactive with viral envelope glycoprotein gp41 trimers, and these Abs are concentrated on the path of virus entry by the neonatal FcR in cervical reserve epithelium and in vaginal epithelium. This local Ab production and delivery system correlated spatially and temporally with the maturation of local protection against high-dose pathogenic SIV vaginal challenge. Thus, designing vaccines to elicit production and concentration of Abs at mucosal frontlines could aid in the development of an effective vaccine to protect women against HIV-1.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25135832      PMCID: PMC4157131          DOI: 10.4049/jimmunol.1400820

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Reinterpretation of human immunodeficiency virus western blot patterns.

Authors:  S Zolla-Pazner; M K Gorny; W J Honnen; A Pinter
Journal:  N Engl J Med       Date:  1989-05-11       Impact factor: 91.245

3.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors:  J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

4.  B lymphocytes express and lose syndecan at specific stages of differentiation.

Authors:  R D Sanderson; P Lalor; M Bernfield
Journal:  Cell Regul       Date:  1989-11

5.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

6.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia.

Authors:  F Smedts; F Ramaekers; S Troyanovsky; M Pruszczynski; H Robben; B Lane; I Leigh; F Plantema; P Vooijs
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

8.  Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Authors:  R I Connor; D C Montefiori; J M Binley; J P Moore; S Bonhoeffer; A Gettie; E A Fenamore; K E Sheridan; D D Ho; P J Dailey; P A Marx
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Oligomeric nature of transmembrane glycoproteins of HIV-2: procedures for their efficient dissociation and preparation of Western blots for diagnosis.

Authors:  B S Parekh; C P Pau; T C Granade; M Rayfield; K M De Cock; H Gayle; G Schochetman; J R George
Journal:  AIDS       Date:  1991-08       Impact factor: 4.177

Review 10.  Identifying epitopes of HIV-1 that induce protective antibodies.

Authors:  Susan Zolla-Pazner
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

View more
  40 in total

1.  Vaccine-Associated Maintenance of Epithelial Integrity Correlated With Protection Against Virus Entry.

Authors:  L Shang; A J Smith; L Duan; K E Perkey; S Wietgrefe; M Zupancic; P J Southern; R P Johnson; J V Carlis; A T Haase
Journal:  J Infect Dis       Date:  2018-09-08       Impact factor: 5.226

2.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Authors:  Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

Authors:  Brian Moldt; Khoa M Le; Diane G Carnathan; James B Whitney; Niccole Schultz; Mark G Lewis; Erica N Borducchi; Kaitlin M Smith; Joseph J Mackel; Shelby L Sweat; Andrew P Hodges; Adam Godzik; Paul W H I Parren; Guido Silvestri; Dan H Barouch; Dennis R Burton
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  Harnessing Novel Imaging Approaches to Guide HIV Prevention and Cure Discoveries-A National Institutes of Health and Global HIV Vaccine Enterprise 2017 Meeting Report.

Authors:  Brigitte E Sanders-Beer; Yegor Voronin; David McDonald; Anjali Singh
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-05       Impact factor: 2.205

Review 5.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 6.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 7.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

8.  Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.

Authors:  Egidio Brocca-Cofano; Cuiling Xu; Katherine S Wetzel; Mackenzie L Cottrell; Benjamin B Policicchio; Kevin D Raehtz; Dongzhu Ma; Tammy Dunsmore; George S Haret-Richter; Karam Musaitif; Brandon F Keele; Angela D Kashuba; Ronald G Collman; Ivona Pandrea; Cristian Apetrei
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

9.  Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates.

Authors:  Susan Zolla-Pazner
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

10.  HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.

Authors:  Wilton B Williams; Hua-Xin Liao; M Anthony Moody; Thomas B Kepler; S Munir Alam; Feng Gao; Kevin Wiehe; Ashley M Trama; Kathryn Jones; Ruijun Zhang; Hongshuo Song; Dawn J Marshall; John F Whitesides; Kaitlin Sawatzki; Axin Hua; Pinghuang Liu; Matthew Z Tay; Kelly E Seaton; Xiaoying Shen; Andrew Foulger; Krissey E Lloyd; Robert Parks; Justin Pollara; Guido Ferrari; Jae-Sung Yu; Nathan Vandergrift; David C Montefiori; Magdalena E Sobieszczyk; Scott Hammer; Shelly Karuna; Peter Gilbert; Doug Grove; Nicole Grunenberg; M Juliana McElrath; John R Mascola; Richard A Koup; Lawrence Corey; Gary J Nabel; Cecilia Morgan; Gavin Churchyard; Janine Maenza; Michael Keefer; Barney S Graham; Lindsey R Baden; Georgia D Tomaras; Barton F Haynes
Journal:  Science       Date:  2015-07-30       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.